Performant Healthcare, Inc. Announces Financial Results for First Quarter 2025

PLANTATION, Fla.–(BUSINESS WIRE)–Performant Healthcare, Inc. (Nasdaq: PHLT), a leading provider of healthcare payment integrity services, today reported the following financial results for its first quarter ended March 31, 2025:


First Quarter 2025 Financial Highlights

  • Total revenue of $33.3 million, compared to total revenue of $27.3 million in the prior year period.
  • Healthcare revenue of $33.2 million, compared to $25.8 million in the prior year period, an increase of approximately 29%.
  • Net loss of $0.1 million, or $0.00 per diluted share, compared to net loss of $4.0 million, or $(0.05) per diluted share, in the prior year period.
  • Adjusted EBITDA of $3.3 million, compared to $(1.2) million in the prior year period.
  • Adjusted net income was $1.2 million, or $0.02 per diluted share, compared to adjusted net loss of $3.0 million, or $(0.04) per diluted share, in the prior year period.

First Quarter 2025 Results

Total revenue in the first quarter of 2025 was $33.3 million, an increase of 22% from total revenue of $27.3 million in the prior year period. Healthcare revenue was $33.2 million in the first quarter of 2025, representing an increase of approximately 29% from $25.8 million in the prior year period. Claims-based services revenue in the first quarter of 2025 was $17.1 million, while revenue from eligibility-based services in the first quarter was $16.1 million, an increase of 38% and 20%, respectively, over the same prior year period.

“Our first quarter revenue and profitability exceeded expectations, underscoring our commitment to a results-driven healthcare strategy,” stated Simeon Kohl, CEO of Performant. «Our quarterly results highlight the demand for Performant’s services and the robustness of our business model. We saw solid growth across both government and commercial clients in the quarter with the majority of growth continuing to come from commercial clients. In the first quarter, we implemented 13 commercial programs, estimated to contribute between $4.5 million and $5.0 million in annualized revenue at steady state. Amid an uncertain political and healthcare environment, Performant is well-positioned to provide clients with certainty and savings. Our mission is unchanged, we are committed to reducing wasteful spend in the healthcare system and we are dedicated to delivering sustainable growth and profitable expansion for our shareholders.»

Net loss for the first quarter was $0.1 million, or $0.00 per diluted share, compared to a net loss of $4.0 million, or $(0.05) per diluted share, in the prior year period. Adjusted EBITDA for the first quarter was $3.3 million as compared to $(1.2) million in the prior year period. Adjusted net income for the first quarter was $1.2 million, or $0.02 per share on a diluted basis, compared to adjusted net loss of $3.0 million, or $(0.04) per diluted share, in the prior year period.

«The strong start to the year gives us confidence to increase full-year adjusted EBITDA and revenue guidance,» said Rohit Ramchandani, Chief Financial Officer. «These solid first-quarter results are a testament to our commitment and execution of the strategy set forth in 2021 when we transitioned to a pure-play healthcare company. With commercial clients, our largest growth area, we continue to see strong momentum driven by solid performance, a healthy pipeline, successful implementations, and a growing backlog of new contract awards that have yet to fully scale. We expect to deliver 2025 healthcare revenues in the range of $133 million to $135 million and adjusted EBITDA in the range of $9 million to $10 million. This increase in guidance reflects our solid first-quarter results and our optimistic outlook for the remainder of the year,» Ramchandani further commented.

Note Regarding Use of Non-GAAP Financial Measures

In this press release, to supplement our consolidated financial statements, the Company presents adjusted EBITDA, adjusted net income (loss), and adjusted net income (loss) per diluted share. These measures are not in accordance with accounting principles generally accepted in the United States of America (US GAAP) and accordingly reconciliations of adjusted EBITDA and adjusted net income (loss) to net income (loss) determined in accordance with US GAAP are included in the “Reconciliation of Non-GAAP Results” table at the end of this press release. We have included adjusted EBITDA and adjusted net income (loss) in this press release because they are key measures used by our management and board of directors to understand and evaluate our core operating performance and trends and to prepare and approve our annual budget. Accordingly, we believe that adjusted EBITDA and adjusted net income (loss) provide useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and board of directors. Our use of adjusted EBITDA and adjusted net income (loss) has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under US GAAP. In particular, many of the adjustments to our US GAAP financial measures reflect the exclusion of items, specifically interest, tax, and depreciation and amortization expenses, equity-based compensation expense and certain other non-operating expenses, that are recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be calculated differently from similarly titled non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes. In regard to forward looking non-GAAP guidance, we are not able to reconcile the forward-looking non-GAAP adjusted EBITDA measure to the closest corresponding GAAP measure without unreasonable efforts because we are unable to predict the ultimate outcome of certain significant items. These items include, but are not limited to, impacts associated with interest expense, and depreciation and amortization expenses.

Earnings Conference Call

The Company will hold a conference call to discuss its first quarter 2025 results today at 5:00 p.m. Eastern. A live webcast of the call may be accessed on the Investor Relations section of the Company’s website at investors.performantcorp.com. To dial into the call you can dial 800-717-1738 or 646-307-1865.

A replay of the call will be available on the Company’s website or by dialing 844-512-2921 (domestic) or 412-317-6671 (international) and entering the passcode 1176510. The telephonic replay will be available approximately three hours after the call, through May 15, 2025.

About Performant Healthcare, Inc.

Performant supports healthcare payers in identifying, preventing, and recovering waste and improper payments by leveraging advanced technology, analytics and proprietary data assets. Performant works with leading national and regional healthcare payers to provide eligibility-based, also known as coordination-of-benefits (COB) services, as well as claims-based services, which includes the audit and identification of improperly paid claims. Performant is a leading provider of these services in both government and commercial healthcare markets. Performant also provides advanced reporting capabilities, support services, customer care, and stakeholder training programs designed to mitigate future instances of improper payments.

To learn more, please visit http://www.performanthealthcare.com

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s outlook for revenues, net income (loss), adjusted EBITDA in 2025 and beyond, our commercial client growth strategy, and our estimated revenue from commercial programs implemented in the first quarter of 2025. These forward-looking statements are based on current expectations, estimates, assumptions, and projections that are subject to change and actual results may differ materially from the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s ability to generate revenue following long implementation periods associated with new customer contracts; the high level of revenue concentration among our largest customers; client relationships and the Company’s ability to maintain such client relationships; many of the Company’s customer contracts are subject to periodic renewal, are not exclusive, do not provide for committed business volumes; anticipated trends and challenges in the Company’s business and competition in the markets in which it operates; the Company’s indebtedness and compliance, or failure to comply, with restrictive covenants in the Company’s credit agreement; opportunities and expectations for growth in the various markets in which the Company operates; the Company’s ability to hire and retain employees with specialized skills that are required for its healthcare business; downturns in domestic or global economic conditions and other macroeconomic factors; the Company’s ability to generate sufficient cash flows to fund our ongoing operations and other liquidity needs; the impact of public health pandemics such as COVID-19 on the Company’s business and operations, opportunities and expectations for the markets in which the Company operates; the impacts of a failure of the Company’s operating systems or technology infrastructure or those of third-party vendors and subcontractors; the impacts of a cybersecurity breach or related incident to the Company or any of the Company’s third-party vendors and subcontractors; the adaptability of the Company’s technology platform to new markets and processes; the Company’s ability to invest in and utilize our data and analytics capabilities to expand its capabilities; the Company’s growth strategy of expanding in existing markets and considering strategic alliances or acquisitions; the Company’s ability to maintain, protect and enhance its intellectual property; expectations regarding future expenses; expected future financial performance; and the Company’s ability to comply with and adapt to industry regulations and compliance demands.

More information on potential factors that could affect the Company’s financial condition and operating results is included from time to time in the «Risk Factors» and «Management’s Discussion and Analysis of Financial Condition and Results of Operations» sections of the Company’s annual report on Form 10-K for the year ended December 31, 2024 and subsequently filed reports on Forms 10-Q and 8-K. The forward-looking statements are made as of the date of this press release and the Company does not undertake to update any forward-looking statements to conform these statements to actual results or revised expectations.

PERFORMANT HEALTHCARE, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(In thousands, except par value amounts)

 

 

March 31,
2025

December 31,
2024

 

(Unaudited)

 

Assets

 

 

Current assets:

 

 

Cash and cash equivalents

$

9,981

 

$

9,292

 

Trade accounts receivable, net of allowance for credit losses

 

14,713

 

 

14,165

 

Contract assets

 

13,059

 

 

10,876

 

Prepaid expenses and other current assets

 

4,217

 

 

3,991

 

Income tax receivable

 

 

 

34

 

Total current assets

 

41,970

 

 

38,358

 

Property, equipment, and software, net

 

14,025

 

 

14,021

 

Goodwill

 

47,372

 

 

47,372

 

Debt issuance costs

 

359

 

 

416

 

Right-of-use assets

 

867

 

 

826

 

Other assets

 

772

 

 

781

 

Total assets

$

105,365

 

$

101,774

 

Liabilities and Stockholders’ Equity

 

 

Current liabilities:

 

 

Accrued salaries and benefits

 

10,699

 

 

8,502

 

Accounts payable

 

1,347

 

 

482

 

Other current liabilities

 

1,807

 

 

2,091

 

Income taxes payable

 

35

 

 

 

Contract liabilities

 

591

 

 

753

 

Estimated liability for appeals and disputes

 

543

 

 

517

 

Deferred asset acquisition payments

 

1,216

 

 

1,243

 

Lease liabilities

 

163

 

 

383

 

Total current liabilities

 

16,401

 

 

13,971

 

Long-term loan payable

 

8,000

 

 

8,000

 

Deferred asset acquisition payments

 

2,015

 

 

2,686

 

Lease liabilities

 

723

 

 

462

 

Other liabilities

 

94

 

 

156

 

Total liabilities

 

27,233

 

 

25,275

 

Commitments and contingencies

 

 

Stockholders’ equity:

 

 

Common stock, $0.0001 par value. Authorized, 500,000 shares at March 31, 2025 and December 31, 2024 respectively; issued and outstanding 78,309 and 78,309 shares at March 31, 2025 and December 31, 2024, respectively

 

8

 

 

8

 

Additional paid-in capital

 

153,402

 

 

151,688

 

Accumulated deficit

 

(75,278

)

 

(75,197

)

Total stockholders’ equity

 

78,132

 

 

76,499

 

Total liabilities and stockholders’ equity

$

105,365

 

$

101,774

 

PERFORMANT HEALTHCARE, INC. AND SUBSIDIARIES

Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

 

 

Three Months Ended

March 31,

 

2025

2024

Revenues

$

33,269

 

$

27,334

 

Operating expenses:

 

 

Salaries and benefits

 

25,358

 

 

23,221

 

Other operating expenses

 

7,761

 

 

8,034

 

Total operating expenses

 

33,119

 

 

31,255

 

Income (loss) from operations

 

150

 

 

(3,921

)

Interest expense

 

(289

)

 

(186

)

Interest income

 

98

 

 

106

 

Loss before provision for income taxes

 

(41

)

 

(4,001

)

Provision for income taxes

 

40

 

 

16

 

Net loss

$

(81

)

$

(4,017

)

Net loss per share

 

 

Basic

$

 

$

(0.05

)

Diluted

$

 

$

(0.05

)

Weighted average shares

 

 

Basic

 

78,309

 

 

76,920

 

Diluted

 

78,309

 

 

76,920

 

 

PERFORMANT HEALTHCARE, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

Three Months Ended

March 31,

 

2025

2024

Cash flows from operating activities:

 

 

Net loss

$

(81

)

$

(4,017

)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

Loss on disposal of assets

 

 

 

29

 

Depreciation and amortization

 

1,452

 

 

1,398

 

Right-of-use assets amortization

 

146

 

 

108

 

Stock-based compensation

 

1,714

 

 

957

 

Interest expense from debt issuance costs

 

56

 

 

58

 

Interest accretion on deferred asset acquisition

 

67

 

 

 

Changes in operating assets and liabilities:

 

 

Trade accounts receivable

 

(548

)

 

3,301

 

Contract assets

 

(2,183

)

 

(1,000

)

Prepaid expenses and other current assets

 

(226

)

 

(480

)

Income tax receivable

 

34

 

 

335

 

Other assets

 

3

 

 

325

 

Accrued salaries and benefits

 

2,197

 

 

(1,850

)

Accounts payable

 

865

 

 

1,424

 

Contract liabilities and other current liabilities

 

(446

)

 

(365

)

Income taxes payable

 

35

 

 

7

 

Estimated liability for appeals and disputes

 

26

 

 

(10

)

Lease liabilities

 

(146

)

 

(106

)

Other liabilities

 

(61

)

 

7

 

Net cash provided by operating activities

 

2,904

 

 

121

 

Cash flows from investing activities:

 

 

Purchase of property, equipment, and software

 

(1,450

)

 

(3,652

)

Net cash used in investing activities

 

(1,450

)

 

(3,652

)

Cash flows from financing activities:

 

 

Debt issuance costs paid

 

 

 

(14

)

Deferred asset acquisition payments made

 

(765

)

 

 

Net cash used in financing activities

 

(765

)

 

(14

)

Net increase (decrease) in cash and cash equivalents

 

689

 

 

(3,545

)

Cash and cash equivalents at beginning of period

 

9,292

 

 

7,333

 

Cash and cash equivalents at end of period

$

9,981

 

$

3,788

 

Non-cash investing activities:

 

 

Deferred asset acquisition payments

$

 

$

3,718

 

Supplemental disclosures of cash flow information:

 

 

Cash paid (received) for income taxes

$

4

 

$

(304

)

Cash paid for interest

$

227

 

$

127

 

PERFORMANT HEALTHCARE, INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Results

(In thousands, except per share amount)

(Unaudited)

 

 

Three Months Ended

March 31,

 

2025

2024

 

(in thousands)

Adjusted EBITDA:

 

 

Net income (loss)

$

(81

)

$

(4,017

)

Provision for income taxes

 

40

 

 

16

 

Interest expense (1)

 

289

 

 

186

 

Interest income

 

(98

)

 

(106

)

Stock-based compensation

 

1,714

 

 

957

 

Depreciation and amortization

 

1,452

 

 

1,398

 

Severance expenses (3)

 

 

 

336

 

Other

 

6

 

 

 

Adjusted EBITDA

$

3,322

 

$

(1,230

)

 

Three Months Ended

March 31,

 

2025

2024

 

(in thousands)

Adjusted Net Income (Loss):

 

 

Net income (loss)

$

(81

)

$

(4,017

)

Stock-based compensation

 

1,714

 

 

957

 

Amortization of debt issuance costs (2)

 

63

 

 

58

 

Severance expenses (3)

 

 

 

336

 

Other

 

6

 

 

 

Tax adjustments (4)

 

(490

)

 

(372

)

Adjusted net income (loss)

$

1,212

 

$

(3,038

)

 

Three Months Ended

March 31,

 

2025

2024

 

(in thousands)

Adjusted Net Income (Loss) Per Diluted Share:

 

 

Net income (loss)

$

(81

)

$

(4,017

)

Plus: Adjustment items per reconciliation of adjusted net income (loss)

 

1,293

 

 

979

 

Adjusted net income (loss)

$

1,212

 

$

(3,038

)

Adjusted net income (loss) per diluted share

$

0.02

 

$

(0.04

)

Diluted average shares outstanding (5)

 

79,407

 

 

76,920

 

(1)

Primarily represents interest expense and amortization of debt issuance costs related to our Credit Agreement.

(2)

Represents amortization of debt issuance costs related to our Credit Agreement.

(3)

Represents severance expenses incurred in connection with a reduction in force for our non-healthcare recovery services.

(4)

Represents tax adjustments assuming a marginal tax rate of 27.5% at full profitability.

(5)

While net loss for the three months ended March 31, 2025 is ($81), the computation of adjusted net income (loss) results in adjusted net income of $1,212. Therefore, the calculation of the adjusted net income (loss) per diluted share for the three months ended March 31, 2025 includes dilutive common share equivalents of 1,098 added to the basic weighted average shares of 78,309.

We are providing the following historical breakdown of the quarterly and annual revenue contributions under the contribution breakdowns of our healthcare revenue results for the three months ended March 31, 2025, and for the years ended December 31, 2024, 2023 and 2022:

PERFORMANT HEALTHCARE, INC. AND SUBSIDIARIES

Quarterly and Annual Revenues

(In thousands)

(Unaudited)

 

 

Three Months Ended

 

March 31, 2025

 

 

Eligibility-based

$

16,082

Claims-based

 

17,104

Healthcare Total

 

33,186

Customer Care / Outsourced Services

 

83

Total

$

33,269

 

 

 

Three Months Ended

 

Year Ended

 

March 31, 2024

June 30, 2024

September 30, 2024

December 31, 2024

December 31, 2024

 

(in thousands)

Eligibility-based

$

13,388

$

14,264

$

16,070

$

18,138

$

61,860

Claims-based

 

12,412

 

13,661

 

14,217

 

16,141

 

56,431

Healthcare Total

 

25,800

 

27,925

 

30,287

 

34,279

 

118,291

Customer Care / Outsourced Services

 

1,534

 

1,437

 

1,232

 

487

 

4,690

Total

$

27,334

$

29,362

$

31,519

$

34,766

$

122,981

 

Three Months Ended

Year Ended

 

March 31, 2023

June 30, 2023

September 30, 2023

December 31, 2023

December 31, 2023

 

(in thousands)

Eligibility-based

$

12,480

$

14,131

$

18,165

$

16,403

$

61,179

Claims-based

 

10,412

 

9,798

 

10,325

 

14,730

 

45,265

Healthcare Total

 

22,892

 

23,929

 

28,490

 

31,133

 

106,444

Recovery

 

19

 

14

 

 

 

33

Customer Care / Outsourced Services

 

2,818

 

1,542

 

1,472

 

1,434

 

7,266

Total

$

25,729

$

25,485

$

29,962

$

32,567

$

113,743

 

Three Months Ended

Year Ended

 

March 31, 2022

June 30, 2022

September 30, 2022

December 31, 2022

December 31, 2022

 

(in thousands)

Eligibility-based

$

14,214

$

12,417

$

13,142

$

13,511

$

53,284

Claims-based

 

9,150

 

9,339

 

10,377

 

12,516

 

41,382

Healthcare Total

 

23,364

 

21,756

 

23,519

 

26,027

 

94,666

Recovery

 

118

 

7

 

41

 

75

 

241

Customer Care / Outsourced Services

 

3,601

 

3,918

 

3,618

 

3,140

 

14,277

Total

$

27,083

$

25,681

$

27,178

$

29,242

$

109,184

 

Contacts

Jon Bozzuto

Investor Relations

925-960-4988

[email protected]

Artículos Relacionados